Literature DB >> 197013

Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.

E N Kitces, P S Morahan, J G Tew, B K Murray.   

Abstract

The effect of immunization with inactivated herpes virus vaccines, including a vaccine free of all nucleic acid, was investigated in a mouse model system. Protection against oral lesions induced by herpes simplex virus type 1 was demonstrated by several criteria: (i) reduction in the incidence and severity of primary oral lesions; (ii) decrease in acute and latent infection of the regional sensory ganglia; and (iii) protection from viral encephalitis and death. The immune response of mice to the vaccine and to subsequent virus challenge was measured by following serum-neutralizing antibody titers.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 197013      PMCID: PMC421057          DOI: 10.1128/iai.16.3.955-960.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization.

Authors:  R W Price; M A Walz; C Wohlenberg; A L Notkins
Journal:  Science       Date:  1975-05-30       Impact factor: 47.728

Review 2.  Experimental evidence for the oncogenic potential of herpes simplex virus.

Authors:  F Rapp; C Reed
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

3.  Cyclic appearance of defective interfering particles of herpes simplex virus and the concomitant accumulation of early polypeptide VP175.

Authors:  B K Murray; N Biswal; J B Bookout; R E Lanford; R J Courtney; J L Melnick
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

4.  Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus.

Authors:  J A Zaia; E L Palmer; P M Feorino
Journal:  J Infect Dis       Date:  1975-12       Impact factor: 5.226

5.  New adjuvants on a polymethylmethacrylate base.

Authors:  J Kreuter; P P Speiser
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

6.  Studies on herpes simplex virus and cancer.

Authors:  J L Melnick; R J Courtney; K L Powell; P A Schaffer; M B Melnick; G R Dreesman; T Anzai; E Adam
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

7.  Correlation of tumor burden with in vitro lymphocyte reactivity and antibodies to herpesvirus tumor-associated antigens in head and neck squamous carcinoma.

Authors:  N A Silverman; J C Alexander; A C Hollinshead; P B Chretien
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

Review 8.  Herpesvirus type 2-related antigens and their relevance to humoral and cell-mediated immunity in patients with cervical cancer.

Authors:  L Aurelian; B C Strnad
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

9.  Comparative diagnostic aspects of herpes simplex virus tumor-associated antigens.

Authors:  M F Notter; J J Docherty
Journal:  J Natl Cancer Inst       Date:  1976-09       Impact factor: 13.506

10.  THE PATHOGENESIS OF HERPES VIRUS ENCEPHALITIS. I. VIRUS PATHWAYS TO THE NERVOUS SYSTEM OF SUCKLING MICE DEMONSTRATED BY FLUORESCENT ANTIBODY STAINING.

Authors:  R T JOHNSON
Journal:  J Exp Med       Date:  1964-02-01       Impact factor: 14.307

View more
  24 in total

Review 1.  Herpes simplex viruses: is a vaccine tenable?

Authors:  Richard J Whitley; Bernard Roizman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.

Authors:  G R Skinner; C Fink; J Melling; C Wiblin; B Thornton; J Hallworth; W Gardner; P McLeish; C Hartley; A Buchan
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

3.  Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment.

Authors:  R J Klein; A E Friedman-Kien; P B Yellin
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

4.  Protective effect of an oral infection with herpes simplex virus type 1 against subsequent genital infection with herpes simplex virus type 2.

Authors:  B Sturn; K E Schneweis
Journal:  Med Microbiol Immunol       Date:  1978-07-04       Impact factor: 3.402

Review 5.  The pathogenesis of acute, latent and recurrent herpes simplex virus infections.

Authors:  R J Klein
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

6.  Immune responses in mice against herpes simplex virus: mechanisms of protection against facial and ganglionic infections.

Authors:  H J Zweerink; D Martinez; R J Lynch; L W Stanton
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

7.  Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation.

Authors:  A al-Ghamdi; R Jennings; H Bentley; C W Potter
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

8.  Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.

Authors:  R J Klein; E DeStefano; E Brady; A E Friedman-Kien
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

9.  Animal studies on the efficacy of vaccination against recurrent herpes.

Authors:  M Scriba
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

10.  Immune response to a DNA free herpes simplex vaccine in man.

Authors:  R Cappel; S Sprecher; F Rickaert; F de Cuyper
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.